← Evidence map

ArticleNaunyn-Schmiedeberg's archives of pharmacology2026

Vigilance for drug safety of darolutamide in the cancer therapies: a disproportionality analysis from the FDA Adverse Event Reporting System.

Zhenquan Wu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2026

this papercites it

Vigilance for drug safety of darolutamide in the cancer therapies: a disproportionality analysis from the FDA Adverse Event Reporting System. | OpenQuestion